Pharmaceutical and life sciences companies are faced with a constant stream of new data flowing into often siloed information systems. About 80% of that information exists in unstructured text that is difficult to extract and use, despite its paramount importance in driving clinical and commercial outcomes. As a result, these organizations find themselves increasingly overwhelmed…

One silver lining of the COVID-19 pandemic is that it has accelerated the rate of change for pharma and life sciences fields in general.  The pandemic has forced a rethink of how to manage clinical trials and treat patients in hospitals and their homes. And the breakneck speed of vaccine development in 2020 could potentially…

Avacta Group, the developer of Affimer biotherapeutics and reagents, provided an update on the Affimer therapeutics development partnership and license agreement with LG Chem Life Sciences, part of the South Korean LG Group, to develop Affimer therapeutics in several disease areas. Avacta has generated a large number of Affimer proteins that bind to the first…